X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Enterin completed the first human clinical trials for ENT-01 which demonstrated that oral administration of its treatment has restored function of the nervous system of the gastrointestinal tract in Parkinson’s patients.
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Enterin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2022
Details:
ENT-01 is administered orally and acts locally on the ENS. It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons.
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Parkinson’s Virtual Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2022
Details:
Dr. Denise Barbut, Enterin's co-founder and CMO, will present the company's latest updates relating to its lead compound, ENT-01, which is currently being developed for the treatment of Parkinson's Disease (PD).
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Pfizer CentreOne is a global CDMO and a leading supplier of Specialty APIs.
